SpaceOAR System RWS in China

Not Applicable

Completed

Brief Summary: This study aims to evaluate the safety and performance of SpaceOAR System when it is used to create space between the rectum and prostate in men undergoing radiotherapy for localized T1-T2 prostate cancer in China via collecting the real word data of SpaceOAR System used, to generate local clinical evidence on Chinese patients.

Detailed Description: This study is a retrospective and prospective, single arm, real world study. For those patients who have already received the SpaceOAR treatment before study kick-off, the data at baseline and the day of procedure will be retrospectively collected. For those patients who will receive SpaceOAR treatment after study kick-off, the clinical data at baseline, the day of procedure and 30 days post procedure will be prospectively collected.

Up to 20 subjects with a pathologically confirmed diagnosis of clinical stage T1 or T2 prostate cancer indicated for radiotherapy will be enrolled, for there are chances of missing data in the real world study. A sample of 14 subjects provides at least 90% power for the primary objective.

Recruitment & Eligibility

Inclusion Criteria

Subjects has provided the written informed consent, willing to participate in clinical data collection and willing to receive visit at 30 days post procedure. (for subjects enrolled prospectively)
Subjects must have been pathologically confirmed prostate cancer with clinical stage T1-T2, and have been treated or will be treated with Space OAR Hydrogel in hospital in Hainan Boao Lecheng medical pilot zone.

Exclusion Criteria- no specific exclusion criteria unless the patients refuse to sign the informed consent.

Exclusion Criteria

Not provided

Arm && Interventions

Group	Intervention	Description
SpaceOAR Treatment Arm	SpaceOAR Treatment	Single arm, up to 20 subjects with a pathologically confirmed diagnosis of clinical stage T1 or T2 prostate cancer indicated for radiotherapy will be enrolled, for there are chances of missing data in the real world study. A sample of 14 subjects provides at least 90% power for the primary objective.

Primary Outcome Measures

Name	Time	Method
Primary Effectiveness Endpoint	Within 10 days post spaceOAR hydrogel administration.	The distance between the posterior prostatic capsule and anterior rectal wall,
Primary Safety Endpoint	Within 30 days following procedure	Subjects with AEs related to SpaceOAR system and/or procedure within 30 days following procedure will be observed.

Secondary Outcome Measures